Navigation Links
Video: MADIT-CRT Trial Results Provide Clinical Evidence That Cardiac Resynchronization Therapy Significantly Slows Heart Failure Progression
Date:9/1/2009

r a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

(1) MADIT-CRT patients are high risk (asymptomatic or mildly symptomatic, New York Heart Association Class I and II). High-risk is defined as QRS width greater than or equal to 130 milliseconds and Left Ventricular Ejection Fraction less than or equal to 30%. The New York Heart Association clinical classifications of heart failure patients rank patients as Class I-II-III-IV, according to the degree of symptoms or functional limits, from asymptomatic to bed ridden.

(2) Left Ventricular Ejection Fraction (LVEF) is a measurement of how well the heart is pumping. People with healthy hearts usually have an LVEF of greater than or equal to 50%. Patients who were candidates for the MADIT-CRT study had an LVEF of less than or equal to 30%.

(3) Ischemic patients suffer from Coronary Artery Disease (CAD).

(4) Trials include MADIT, MADIT-II, CONTAK-CD, and COMPANION.

    Press Contact:
    Paul Donovan
    508-650-8541 (office)
    508-667-5165 (mobile)
    Media Relations
    Boston Scientific Corporation

    David Knutson
    651-260-8288 (mobile)
    Media Relations
'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
2. Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skins Natural Moisture
3. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
4. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
5. Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults
6. Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)
7. Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study
8. Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
9. Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results
10. Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
11. Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 Arbor Pharmaceuticals, LLC. - ... Global Markets Direct,s, ,Arbor Pharmaceuticals, LLC. - Product ... the Arbor Pharmaceuticals, LLC.,s pharmaceutical research and development ... the current therapeutic developmental pipeline of Arbor Pharmaceuticals, ... therapeutics assessment by drug target, mechanism of action ...
(Date:9/30/2014)... , Sept. 30, 2014  Decision Resources Group finds ... Brazil , Russia ... China (BRIC) will see robust expansion as ... favored over surgical procedures. Although revenues will be somewhat ... challenges, prolonged device approval times and demand for low-cost ...
(Date:9/30/2014)... , Sept. 30, 2014  According to their ... of cancer clinical trials is going through a ... and the work of the current clinical trial ... of ,next generation, clinical trials, which will ultimately ... The company has been recognized by ...
Breaking Medicine Technology:Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2
... NEW YORK, Jan. 16, 2012 Reportlinker.com ... is available in its catalogue: ... Medical Devices to 2016 ... gives a thorough analysis of the refurbished ...
... Conn., Jan. 13, 2012 /PRNewswire-iReach/ -- Global Information, ... report, "Insulin Delivery Devices - Global Pipeline Analysis, Competitive Landscape ... http://photos.prnewswire.com/prnh/20120113/CG35865 ) The Insulin Delivery ... 6% to Reach $11 Billion by 2017 ...
Cached Medicine Technology:The Market Outlook for Refurbished Medical Devices to 2016 2The Market Outlook for Refurbished Medical Devices to 2016 3The Market Outlook for Refurbished Medical Devices to 2016 4Insulin Delivery Devices - Increasing Prevalence of Diabetes to Drive the Market 2Insulin Delivery Devices - Increasing Prevalence of Diabetes to Drive the Market 3Insulin Delivery Devices - Increasing Prevalence of Diabetes to Drive the Market 4
(Date:10/1/2014)... Farmington Company today announced it ... and visual identity helping brokers, consultants and companies ... to create greater benefit communication synergies. They unveiled ... empowering customers to better leverage Farmington Company’s industry-tested ... of the rebrand is the refreshed tagline: For ...
(Date:10/1/2014)... finding from Duke Medicine suggests that some people who ... be hard-wired to gain weight when exposed to chronic ... estimated 13 percent of people, all of whom are ... could help them reduce heart disease with simple interventions ... , "Genetic susceptibility, psychosocial stress and metabolic factors act ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Between 23 ... in the U.S., according to figures from the National ... Diseases Association (AARDA), and many of them have something ... of having undiagnosed celiac disease. Gluten Free Therapeutics, ... awareness of undiagnosed celiac disease by publishing a series ...
(Date:10/1/2014)... 01, 2014 Diet Doc understands that many ... lose weight and their dieting attempts could be easily sabotaged ... hormone diet treatments into their programs as a ... see fast and effective weight loss results, it also allows ... habits to maintain their weight for the future. , Earlier ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Anti Aging ... and skin rejuvenating destination of choice, is announcing a ... October through to December. , “We’re doing this because ... possible to our top skin clinic in Toronto,” says ... do so much at Anti Aging Clinic, including laser ...
Breaking Medicine News(10 mins):Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2
... be releasing both Raima Database Manager (RDM) products ... version 9.1 and RDM Server will be released ... RDM,s high availability by providing replication between RDM ... provide developers of embedded systems with an easy ...
... shortened course of radiation therapy for prostate cancer ... PSA response for early-stage prostate cancer and has ... to a March 15 study in the ... journal of the American Society for Radiation Oncology ...
... and getaway destinations are affected, studies find , , SUNDAY, March ... allergies can be a burden on a family,s finances and ... to be presented in Washington, D.C., at the annual meeting ... how these common conditions can have a wide impact on ...
... Manufacturers Association issued the following statement from its president ... to President Obama,s nomination of Dr. Margaret Hamburg as ... (FDA), his nomination of Dr. Joshua Sharfstein as Principal ... a White House Food Safety Working Group:"We applaud President ...
... have exams, even if they have problems, study finds, , , ... coverage, or no health care coverage, are less likely to ... according to a new study. , The finding stems from ... part in the National Health Interview Survey from 1997 through ...
... in health care recruiting and staffing. Individuals have the choice of ... working with an established Health Career Agents office. , ... ... Agents now has three ways for qualified individuals to get involved ...
Cached Medicine News:Health News:Birdstep Technology Announces The Dual Upcoming Release Of Its Raima Database Manager Products 2Health News:Birdstep Technology Announces The Dual Upcoming Release Of Its Raima Database Manager Products 3Health News:Early results favorable for 5-day radiation treatment of early stage prostate cancer 2Health News:Child's Food Allergies Take Toll on Family Plans 2Health News:Grocery Manufacturers Association Statement Regarding President Obama's Nomination of FDA Commissioner 2Health News:Eye Care Checkups Tied to Insurance Status 2Health News:Health Career Agents Announces Three Options for Involvement in Health Care Recruiting and Staffing 2Health News:Health Career Agents Announces Three Options for Involvement in Health Care Recruiting and Staffing 3
Philadelphia™ Collar - Plastazote® with plastic anterior and posterior reinforcements. Hook-and-pile closure straps. Chin cradle reduces rotation. Occipital and mandibular pieces may be int...
... a lightweight patient friendly brace utilizing the latest ... The Escort provides patients with a lightweight brace ... Superior comfort and improved patient compliance is the ... Escort Hip brace is the result of a ...
... Management Systems are designed and engineered to ... your patients. Innovative new options increase function ... on the most successful patented features of ... clamping disk design and the tremendous versatility ...
Distinct male and female designs for proper anatomical fit. Hip and pelvic components sized independently. Rigid posterior tongue minimizes pelvic rotation. Available in black or white plastic. Aggre...
Medicine Products: